Abstract
Favorable acute myeloid leukemia (AML) patients (pts.) demonstrate a relatively good outcome with standard induction; thus, pts. are generally not addressed to allogeneic transplant in first remission. However, it is not clear if also in a real-life setting, the outcome is homogeneous in the different favorable molecular groups and which are the parameters significantly associated to an increased relapse risk, useful to suggest the need of an intensified approach. In order to clarify this point, we collected clinical data on consecutive unselected AML pts. assigned to favorable category (modified ELN 2010 due to the inclusion of double-mutated CEBPA-positive cases), diagnosed and treated in six centers of the Italian network Rete Ematologica Lombarda (REL) from 2007 to 2015. We assessed response (CR, mCR), relapse rate (CIR), and outcome (OS, DFS) after first-line treatment. A total of 201 pts. was studied and the analysis was performed globally and in each molecular group: t(8;21)(q22;q22)/RUNX1-RUNX1T1 (30 pts., 14.9%), inv. (16)(p13q22) or t(16;16)(p13q22)/CBFB-MIH11 (35 pts., 17.4%), normal karyotype and mutated NPM1 and negative FLT3-ITD (116 pts., 57.7%) or double-mutated CEBPA (CEBPAdm) (20 pts., 10%). Complete remission...Continue Reading
References
Feb 12, 1999·Leukemia·M J Pongers-WillemseJ J van Dongen
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdC D Bloomfield
May 3, 2002·Blood·Stéphanie NguyenHervé Dombret
May 31, 2002·Blood·Christian ThiedeThomas Illmer
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Liang-In LinHwei-Fang Tien
Jun 24, 2005·Leukemia·N I NogueraF Lo-Coco
Jul 30, 2005·Blood·Konstanze DöhnerHartmut Döhner
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Dec 31, 2005·Blood·Roberto CairoliEnrica Morra
Mar 17, 2006·Leukemia·P GorelloB Falini
Nov 3, 2009·Blood·Hartmut DöhnerUNKNOWN European LeukemiaNet
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heiko BeckerClara D Bloomfield
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea CorbaciogluKonstanze Döhner
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan KrönkeKonstanze Döhner
Aug 10, 2012·Blood·John A Liu YinAlan K Burnett
Sep 6, 2012·Nature Reviews. Clinical Oncology·Jan J CornelissenGert J Ossenkoppele
Sep 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Krzysztof MrózekClara D Bloomfield
Jan 17, 2013·Blood·Eric JourdanUNKNOWN French AML Intergroup
Mar 29, 2013·Blood·Hong-Hu ZhuXiao-Jun Huang
May 8, 2013·European Journal of Haematology·Montserrat HoyosJorge Sierra
May 10, 2013·Blood·Nona ShayegiUNKNOWN Study Alliance Leukemia (SAL)
Aug 14, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettDonald Milligan
May 13, 2014·Haematologica·Max HubmannKarsten Spiekermann
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Nov 6, 2015·Annals of Hematology·Jae-Sook AhnDennis Dong Hwan Kim
Dec 5, 2015·Haematologica·Christophe WillekensUNKNOWN French AML Intergroup
Jan 21, 2016·The New England Journal of Medicine·Adam IveyUNKNOWN UK National Cancer Research Institute AML Working Group
Aug 1, 2012·Leukemia Supplements·R CairoliE Morra
Nov 30, 2016·Blood·Hartmut DöhnerClara D Bloomfield